Your session is about to expire
← Back to Search
ZILRETTA™ for Frozen Shoulder
Study Summary
This trial is testing a new pain medication for people with a common condition that causes pain and loss of range of motion.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You feel moderate to severe pain (5/10 or higher) when you join the study.You have a mental health condition that is currently being treated.You have a painful joint condition in a different part of your body that affects how you feel pain in the study joint.You were diagnosed with a condition called idiopathic adhesive capsulitis (frozen shoulder) within the last 6 months.You have been diagnosed with osteoarthritis in either your same-side (ipsilateral) or opposite-side (contralateral) shoulder.
- Group 1: ZILRETTA
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How is triamcinolone acetonide extended-release injectable suspension typically utilized therapeutically?
"Triamcinolone acetonide extended-release injectable suspension is a viable medical solution to treat ulcerative colitis, hand ailments and neurological conditions."
Are there any other research projects that have investigated triamcinolone acetonide extended-release injectable suspension?
"Currently, 41 clinical trials are studying triamcinolone acetonide extended-release injectable suspension. Out of these active studies, 8 have attained Phase 3 status. Although the majority of research for this medication is conducted in Columbia, Missouri, there are 75 medical centres conducting related experiments."
What is the current magnitude of research participants in this trial?
"Affirmative. According to the clinicaltrials.gov platform, this clinical trial is actively enrolling subjects and was first posted on June 21st 2019 with its most recent revision dating back to April 5th 2021. The research aims to recruit 50 participants from a single site."
Is the age limit for joining this clinical trial higher than thirty years?
"This clinical trial allows applicants aged 18-80 to join the study. Additionally, there are 6 studies designed specifically for those younger than 18 and 60 more tailored towards seniors above 65 years of age."
Are there any open slots left in this research trial?
"Clinicaltrials.gov assesses that this medical investigation is actively recruiting patients, having been posted on June 21st 2019 and recently updated on April 5th 2021."
Is it safe to administer triamcinolone acetonide extended-release injectable suspension on humans?
"As it is only a Phase 1 trial, with limited evidence regarding efficacy and safety, triamcinolone acetonide extended-release injectable suspension received an overall score of one."
May I register for the trial?
"This medical experiment is seeking 50 individuals aged 18-80 that have recently developed adhesive capsulitis of the shoulder, accompanied by a degree of pain rated 5/10 or higher. These potential participants must also be amenable to return for follow up evaluations at 1 month, 3 months, 6 months and 12 months after receiving the injection."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger